QC
KNSA icon

Quantedge Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Quantedge Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,545
Closed -$270K – 65
2025
Q4 		$270K Sell
6,545
-8,500
-56% -$341K 0.13% 63
2025
Q3 		$584K Buy
+15,045
New +$489K 0.32% 41

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Quantedge Capital's KNSA Position: Q1 2026 in Review

Quantedge Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 6,545 shares — an estimated $270K sold.

Quantedge Capital first reported a position in KNSA in Q3 2025 and held it in 2 quarters. The position peaked at $584K in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Quantedge Capital reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quantedge Capital sold 6,545 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $270K.
  • Quantedge Capital first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Quantedge Capital's Kiniksa Pharmaceuticals position peaked at $584K in Q3 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Quantedge Capital's 13F filing for Q1 2026, filed 12 May 2026.